GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE™ REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENT December 21, 2020
GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients December 8, 2020
GT Biopharma Announces Former Abraxis CEO, Bruce J. Wendel as Vice Chairman of GTBP Board of Directors November 17, 2020
GT Biopharma Announces Publication of GTB-3550 TriKE Interim Results at the Prestigious 62nd American Society of Hematology (ASH) Annual Meeting November 12, 2020
GT Biopharma Announces Publication of Trike(TM) Results Targeting Multiple B7H3 Positive Cancers October 21, 2020
